Tag Archives: HIMX

Oppenheimer Remains a Sell on Himax Technologies (HIMX)

Oppenheimer analyst Andrew Uerkwitz maintained a Sell rating on Himax Technologies (HIMX – Research Report) yesterday and set a price target of $4. The company’s shares closed yesterday at $4.82, close to its 52-week low of $4.74. Uerkwitz wrote: “HIMX

Analysts Offer Insights on Consumer Goods Companies: Himax Technologies (NASDAQ: HIMX) and 3D Systems (NYSE: DDD)

Analysts fell to the sidelines weighing in on Himax Technologies (NASDAQ:HIMX) and 3D Systems (NYSE:DDD) with neutral ratings,indicating that the experts are neither bullish nor bearish on the stocks. Himax Technologies (HIMX) In a report released yesterday, Sujeeva De Silva

Himax Technologies (HIMX) Receives a Sell from Oppenheimer

In a report released today, Andrew Uerkwitz from Oppenheimer maintained a Sell rating on Himax Technologies (NASDAQ: HIMX), with a price target of $4. The company’s shares closed yesterday at $6.62, close to its 52-week low of $5.97. Uerkwitz wrote:

Analysts Offer Insights on Consumer Goods Companies: Himax Technologies (NASDAQ: HIMX) and NeoPhotonics (NYSE: NPTN)

There’s a lot to be optimistic about in the Consumer Goods sector as 2 analysts just weighed in on Himax Technologies (NASDAQ: HIMX) and NeoPhotonics (NYSE: NPTN) with bullish sentiments. Himax Technologies (NASDAQ: HIMX) Northland Securities analyst Gus Richard reiterated

Oppenheimer Keeps Their Sell Rating on Himax Technologies

Oppenheimer analyst Andrew Uerkwitz reiterated a Sell rating on Himax Technologies (NASDAQ: HIMX) today and set a price target of $4. The company’s shares closed yesterday at $8.20. Uerkwitz wrote: “Our Underperform rating has been and continues to be based

Wednesday’s Midday Stock Update: Conatus Pharmaceuticals (CNAT), Biocept Inc (BIOC), Chicago Bridge (CBI), Inovio Pharmaceuticals (INO), Himax Technologies (HIMX)

So far Wednesday, January 24, NASDAQ is down -2.75% and the S&P is down -0.92%. Here are this morning’s most active stocks: Conatus Pharmaceuticals (NASDAQ:CNAT), Biocept Inc (NASDAQ:BIOC), Chicago Bridge (NYSE:CBI), Inovio Pharmaceuticals (NASDAQ:INO) and Himax Technologies (NASDAQ:HIMX). Conatus Pharmaceuticals